---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-033618"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:50:10.936676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics reports FY2021 net loss of $51.2M; cash at $291.1M

## Summary
- Net loss of $18.4M in Q4'21 and $51.2M for FY2021, vs $8.7M and $26.5M in 2020.
- Cash and equivalents $291.1M as of Dec 31, 2021, including $190.7M net from Nov 2021 IPO.
- R&D expenses $12.4M in Q4 ($35.9M FY), up from $6.7M ($21.1M) YoY on preclinical studies.
- On track to submit IND for ENTR-601-44 (DMD exon 44) in 2H 2022.
- Appointed Jared Cohen, PhD, JD as General Counsel in January 2022.

## SEC filing metadata
- accession: 0001104659-22-033618
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/0001104659-22-033618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/tm228415d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-033618
- JSON: https://secwatch.observer/filing/0001104659-22-033618.json
- Plain text: https://secwatch.observer/filing/0001104659-22-033618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.